PMID- 31125734
OWN - NLM
STAT- MEDLINE
DCOM- 20200817
LR  - 20200817
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 402
DP  - 2019 Jul 15
TI  - Lack of independent mood-enhancing effect for dopaminergic medications in early 
      Parkinson's disease.
PG  - 81-85
LID - S0022-510X(19)30225-4 [pii]
LID - 10.1016/j.jns.2019.05.009 [doi]
AB  - BACKGROUND: A direct antidepressant effect has been reported for certain 
      dopaminergic medications used in the treatment of Parkinson's disease (PD). 
      OBJECTIVE: To examine whether dopaminergic medications may exert differential 
      effects on mood in early PD. METHODS: We analyzed prospectively-collected 5-year 
      data on 405 early, drug-naive (at baseline) PD patients enrolled in the 
      Parkinson's Progression Markers Initiative (PPMI) cohort study, initiated on 
      levodopa, dopamine agonists (DAs), or monoamine-oxidase type B inhibitors 
      (iMAO-B) under naturalistic conditions. The outcome for depressive symptoms was 
      the 15-item Geriatric Depression Scale (GDS-15) score. Potential motor and 
      cognitive confounders were measured using the Unified Parkinson's disease Rating 
      Scale (MDS-UPDRS-III) and the Montreal Cognitive Assessment (MoCA). Three 
      statistical models were used to determine medication effects on GDS-15 scores: 
      unadjusted, adjusted, and a marginal structural model. RESULTS: One-third of 
      patients in this cohort met GDS-15 threshold for clinically-significant 
      depressive symptoms (GDS-15 >/= 5). There was a marginal positive effect on GDS-15 
      scores after iMAO-B treatment initiation (-0.35 95%; CI: -0.73, 0.04; p = 0.08). 
      There were no significant interactions between any of the three medication 
      groups, but robust interactions between MoCA scores and both DAs (p = 0.005) and 
      iMAO-B (p = 0.03) use on GDS-15 scores. Specifically, as MoCA scores worsened, 
      DAs yielded a steeper worsening of GDS-15 scores while iMAO-B a moderating effect 
      on GDS-15. CONCLUSION: Dopaminergic medications have no direct effect on mood in 
      early, unselected PD patients.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Espay, Alberto J
AU  - Espay AJ
AD  - James J and Joan A Gardner Family Center for Parkinson's Disease and Movement 
      Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, 
      USA. Electronic address: alberto.espay@uc.edu.
FAU - Foster, Eric D
AU  - Foster ED
AD  - Department of Biostatistics, College of Public Health, University of Iowa, Iowa 
      City, IA, USA.
FAU - Coffey, Christopher S
AU  - Coffey CS
AD  - Department of Biostatistics, College of Public Health, University of Iowa, Iowa 
      City, IA, USA.
FAU - Uribe, Liz
AU  - Uribe L
AD  - Department of Biostatistics, College of Public Health, University of Iowa, Iowa 
      City, IA, USA.
FAU - Caspell-Garcia, Chelsea J
AU  - Caspell-Garcia CJ
AD  - Department of Biostatistics, College of Public Health, University of Iowa, Iowa 
      City, IA, USA.
FAU - Weintraub, Daniel
AU  - Weintraub D
AD  - Department of Neurology, Perelman School of Medicine at the University of 
      Pennsylvania, Philadelphia, PA, USA; Department of Psychiatry, Perelman School of 
      Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of 
      Veterans Affairs, Philadelphia VA Medical Center, Philadelphia, PA, USA.
CN  - Parkinson's Progression Markers Initiative
LA  - eng
PT  - Journal Article
DEP - 20190516
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Antidepressive Agents)
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Dopamine Agonists)
RN  - 46627O600J (Levodopa)
SB  - IM
CIN - J Neurol Sci. 2019 Sep 15;404:70-71. PMID: 31336234
MH  - Affect/*drug effects
MH  - Aged
MH  - Antidepressive Agents/pharmacology/*therapeutic use
MH  - Antiparkinson Agents/pharmacology/*therapeutic use
MH  - Cognition/drug effects
MH  - Depression/*drug therapy
MH  - Disease Progression
MH  - Dopamine Agonists/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Levodopa/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/*drug therapy
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Depression
OT  - Dopamine agonists
OT  - Levodopa
OT  - MAO-B inhibitors
OT  - Mood
OT  - Parkinson's disease
EDAT- 2019/05/28 06:00
MHDA- 2020/08/18 06:00
CRDT- 2019/05/25 06:00
PHST- 2019/02/04 00:00 [received]
PHST- 2019/03/22 00:00 [revised]
PHST- 2019/05/12 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/08/18 06:00 [medline]
PHST- 2019/05/25 06:00 [entrez]
AID - S0022-510X(19)30225-4 [pii]
AID - 10.1016/j.jns.2019.05.009 [doi]
PST - ppublish
SO  - J Neurol Sci. 2019 Jul 15;402:81-85. doi: 10.1016/j.jns.2019.05.009. Epub 2019 
      May 16.